A RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED 52-WEEK STUDY WITH AN OPEN-LABEL EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF BENRALIZUMAB COMPARED TO MEPOLIZUMAB IN THE TREATMENT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) IN PATIENTS RECEIVING STANDARD OF CARE THERAPY
- Registry ID
- D3253C00001
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- ASTRAZENECA CANADA INC
- Start date
- 2020-07-16
- Last update
- 2019-08-21
Conditions
- POLYANGITIS
- EOSINOPHILIC GRANULOMATOSIS
Related clinical trials
- A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF NS-229 IN THE TREATMENT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
- 52-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP, MULTI-CENTRE, NON-INFERIORITY STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DEPEMOKIMAB COMPARED WITH MEPOLIZUMAB IN ADULTS WITH RELAPSING OR REFRACTORY EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) RECEIVING STANDARD OF CARE (SOC) THERAPY
- "ABATACEPT (CTLA4-IG) FOR THE TREATMENT OF RELAPSING, NON-SEVERE, GRANULOMATOSIS WITH POLYANGIITIS (WEGENER'S) (ABROGATE)."
- A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MEPOLIZUMAB IN THE TREATMENT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGITIS IN SUBJECTS RECEIVING STANDARD OF CARE THERAPY
View on source registry